MA33128B1 - Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase - Google Patents

Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase

Info

Publication number
MA33128B1
MA33128B1 MA34175A MA34175A MA33128B1 MA 33128 B1 MA33128 B1 MA 33128B1 MA 34175 A MA34175 A MA 34175A MA 34175 A MA34175 A MA 34175A MA 33128 B1 MA33128 B1 MA 33128B1
Authority
MA
Morocco
Prior art keywords
radical
formula
cycle
represented
possibly substituted
Prior art date
Application number
MA34175A
Other languages
Arabic (ar)
English (en)
Inventor
Harry Finch
John Montana
Niel Monique Bodil Van
Chi-Kit Woo
Jamie Knight
Bohdan Waszkowycz
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42232647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33128(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0902651A external-priority patent/GB0902651D0/en
Priority claimed from GB0908069A external-priority patent/GB0908069D0/en
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA33128B1 publication Critical patent/MA33128B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (I) QUI SONT DES INHIBITEURS DE LA P38 MAP UTILISÉS COMME AGENTS ANTI-INFLAMMATOIRES POUR TRAITER, INTER ALIA, LES MALADIES DES VOIES RESPIRATOIRES. DANS LA FORMULE (I), R1 REPRÉSENTE ALKYLE C1-C6, CYCLOALKYLE C3-C6, PHÉNYLE QUI EST ÉVENTUELLEMENT SUBSTITUÉ, HÉTÉROARYLE MONOCYCLIQUE À 5 OU 6 ÉLÉMENTS QUI EST ÉVENTUELLEMENT SUBSTITUÉ, OU UN RADICAL REPRÉSENTÉ PAR LA FORMULE (II) DANS LEQUEL N EST ÉGAL À 1 OU 2, ET R3 ET R4 REPRÉSENTENT INDÉPENDAMMENT H OU ALKYLE C1-C6, OU R3 ET R4 PRIS ENSEMBLE AVEC L'AZOTE À LAQUELLE ILS SONT LIÉS FORMENT UN CYCLE HÉTÉROCYCLIQUE À 6 ÉLÉMENTS CONTENANT ÉVENTUELLEMENT UN AUTRE HÉTÉROATOME SÉLECTIONNÉ PARMI N ET O; Y REPRÉSENTE -O- OU -S(O)P- DANS LEQUEL P EST ÉGAL À 0, 1 OU 2 ; A REPRÉSENTE ÉVENTUELLEMENT UN RADICAL ARYLÈNE DIVALENT ÉVENTUELLEMENT SUBSTITUÉ, OU UN RADICAL HÉTÉROARYLÈNE MONOCYCLIQUE OU BICYCLIQUE, OU UN RADICAL CYCLOALKYLÈNE DIVALENT C3-C6 COMPRENANT 5 OU 6 ATOMES DE CYCLE, OU UN RADICAL PIPÉRIDINYLÈNE DANS LEQUEL L'AZOTE DE CYCLE EST LIÉE À R2NHC(=O)W- ; W REPRÉSENTE UNE LIAISON, -NH- OU -C(RA)(RB), DANS LEQUEL RA ET RB REPRÉSENTENT INDÉPENDAMMENT H, MÉTHYLE, ÉTHYLE, AMINO, HYDROXYLE OU HALO ; ET R2 REPRÉSENTE UN RADICAL TEL QUE DÉFINI DANS LES REVENDICATIONS.
MA34175A 2009-02-17 2010-02-16 Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase MA33128B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0902651A GB0902651D0 (en) 2009-02-17 2009-02-17 Pharmaceutical compounds and compositions
GB0908069A GB0908069D0 (en) 2009-05-11 2009-05-11 Pharmaceutical compounds and compositions
PCT/GB2010/050257 WO2010094956A1 (fr) 2009-02-17 2010-02-16 Dérivés de triazolopyridine utilisés comme inhibiteurs de la p38 map kinase

Publications (1)

Publication Number Publication Date
MA33128B1 true MA33128B1 (fr) 2012-03-01

Family

ID=42232647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34175A MA33128B1 (fr) 2009-02-17 2010-02-16 Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase

Country Status (19)

Country Link
US (1) US8557797B2 (fr)
EP (1) EP2398798A1 (fr)
JP (1) JP2012517992A (fr)
KR (1) KR20110116030A (fr)
CN (2) CN103483338A (fr)
AU (1) AU2010215261A1 (fr)
BR (1) BRPI1005327A2 (fr)
CA (1) CA2752693A1 (fr)
CL (1) CL2011001977A1 (fr)
CO (1) CO6420344A2 (fr)
EA (1) EA201190119A1 (fr)
IL (1) IL214658A0 (fr)
MA (1) MA33128B1 (fr)
MX (1) MX2011008496A (fr)
PE (1) PE20120655A1 (fr)
SG (1) SG174134A1 (fr)
TN (1) TN2011000380A1 (fr)
WO (1) WO2010094956A1 (fr)
ZA (1) ZA201105993B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054984A1 (fr) * 2007-10-24 2009-04-30 Merck & Co., Inc. Antagonistes de canaux calciques de type t à base de phényle amide hétérocyclique
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
EP2736899A1 (fr) 2011-07-26 2014-06-04 Grünenthal GmbH Dérivés de carboxamide et d'urée aromatiques bicycliques substitués en tant que ligands de récepteur de vanilloïde
KR20140103925A (ko) * 2011-12-09 2014-08-27 키에시 파르마슈티시 엣스. 피. 에이. 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
ME02624B (fr) * 2011-12-09 2017-06-20 Chiesi Farm Spa Inhibiteurs de kinase
SG11201402986RA (en) * 2011-12-09 2014-12-30 Chiesi Farma Spa Kinase inhibitors
EP2875014B1 (fr) 2012-07-17 2017-11-29 Washington University Médicaments anti-mucus et leurs utilisations
CA2914449A1 (fr) * 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Inhibiteurs de kinases
CN105377847A (zh) * 2013-06-06 2016-03-02 奇斯药制品公司 激酶抑制剂
CA2914457A1 (fr) * 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Inhibiteurs de la kinase
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3215141A4 (fr) 2014-11-05 2018-06-06 Flexus Biosciences, Inc. Agents immunorégulateurs
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Utilisation d'inhibiteurs de p38 pour réduire l'expression de dux4

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
WO1997002289A1 (fr) 1995-07-06 1997-01-23 Zeneca Limited Inhibiteurs peptidiques de la fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (fr) 2001-03-16 2002-09-18 Pfizer Products Inc. Dérivés de purine pour le traitement de l'ischémie
EP1458682B1 (fr) 2001-12-20 2006-08-30 Bayer HealthCare AG Derives de 1,4-dihydro-1,4-diphenylpyridine
WO2004072072A1 (fr) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines utilisees comme composes anti-inflammatoires
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
PT1761520E (pt) 2004-06-23 2008-09-15 Lilly Co Eli Inibidores de quinase
EP1609789A1 (fr) 2004-06-23 2005-12-28 Eli Lilly And Company Derives de ureido-pyrazole et leur utilisation comme inhibiteurs de kinase
AP2326A (en) 2004-08-12 2011-11-24 Pfizer Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds
JP2008509985A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー 炎症治療用の新規トリアゾロピリジン化合物
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
US20090012079A1 (en) 2006-02-09 2009-01-08 Russell Andrew Lewthwaite Triazolopyridine Compounds
MX2009001876A (es) 2006-08-21 2009-03-06 Array Biopharma Inc Derivados de acido fenoxifenilacetico 4-sustituidos.
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions

Also Published As

Publication number Publication date
EA201190119A1 (ru) 2012-05-30
KR20110116030A (ko) 2011-10-24
PE20120655A1 (es) 2012-06-07
MX2011008496A (es) 2011-11-18
CN103483338A (zh) 2014-01-01
US8557797B2 (en) 2013-10-15
CL2011001977A1 (es) 2011-11-18
SG174134A1 (en) 2011-10-28
EP2398798A1 (fr) 2011-12-28
TN2011000380A1 (en) 2013-03-27
AU2010215261A1 (en) 2011-09-08
CN102395586A (zh) 2012-03-28
US20120088763A1 (en) 2012-04-12
IL214658A0 (en) 2011-09-27
CA2752693A1 (fr) 2010-08-26
CO6420344A2 (es) 2012-04-16
ZA201105993B (en) 2012-10-31
WO2010094956A1 (fr) 2010-08-26
BRPI1005327A2 (pt) 2019-09-24
JP2012517992A (ja) 2012-08-09

Similar Documents

Publication Publication Date Title
MA33128B1 (fr) Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
EP2423207A3 (fr) Derives de pyrimidone substitues en position 2 par une amine cyclique en tant qu'inhibiteurs de TPK1
EP2261224A3 (fr) Dérivés de 6-(pyridinyl)-4-pyrimidone en tant qu'inhibiteurs de la protéine kinase tau 1
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
MXPA04003007A (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
WO2006044497A3 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
HK1110588A1 (en) Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
NO20050828L (no) lndol-3-svovelderivater
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
MX2007002807A (es) Compuesto 2-morfolino-4-pirimidona.
NO20054330L (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
EP1817312A4 (fr) Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer
WO2006055434A3 (fr) Inhibiteurs de la beta-secretase formes d'amines tertiaires macrocycliques pour le traitement de la maladie d'alzheimer
WO2004089366A8 (fr) Composes bicycliques comme antagonistes du recepteur nr2b
CA2352405A1 (fr) Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
BRPI0411414A (pt) derivados de quinolil amida como antagonistas de cdr-5
EA200501041A1 (ru) Замещенные производные 1-пиперидин-4-ил-4-пирролидин-3-илпиперазина и их применение в качестве антагонистов нейрокининов
SE0403171D0 (sv) New compounds
DE60008218D1 (de) Heterozyklische verbindungen, ihre zwischenprodukte und elastase-inhibitoren